OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Ruff Analyzes Overall Survival in the VELOUR Trial

February 1st 2013

Paul Ruff, MD, from the Witwatersrand, Johannesburg, South Africa, discusses a time-course analysis of overall survival following treatment with ziv-aflibercept in patients with metastatic colorectal cancer, as observed in the VELOUR trial.

Dr. Kim on the Investigation of Regorafenib in mCRC

January 31st 2013

Richard Kim, MD, medical oncologist, Gastrointestinal Oncology Department at Moffitt Cancer Center, discusses studies investigating regorafenib (Stivarga) in metastatic colorectal cancer.

Dr. James Mohler on Androgen Levels in Prostate Cancer

January 30th 2013

James Mohler, MD, Roswell Park Cancer Institute, explains the progress needed to better understand androgen receptors.

Dr. Fanale on Brentuximab Vedotin in High-Risk ALCL

January 30th 2013

Michelle A. Fanale, MD, Associate Professor, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the role of brentuximab vedotin as frontline treatment of systemic anaplastic large cell lymphoma.

Dr. Uesaka on Gemcitabine vs S-1 in Pancreatic Cancer

January 30th 2013

Katsuhiko Uesaka, MD, PhD, from the Shizuoka Cancer Center Hospital in Japan, discusses the JASPAC-01 study that compared gemcitabine to S-1 in Asian patients with resected pancreatic cancer.

Dr. John Byrd on Bruton's Tyrosine Kinase in CLL

January 29th 2013

John C. Byrd, MD, director of the division of hematology at The Ohio State University Comprehensive Cancer Center, discusses the role of Bruton's Tyrosine Kinase (BTK) in chronic lymphocytic leukemia.

Dr. Hugo Ford on the Phase III COUGAR-02 Study

January 29th 2013

Hugo Ford, MD, from the Addenbrooke's Hospital in Cambridge, UK, describes results from the phase III COUGAR-02 study that examined second-line docetaxel in patients with advanced gastroesophageal adenocarcinoma.

Dr. Perez on the Adjuvant Treatment of Breast Cancer

January 28th 2013

Edith A. Perez, MD, from the Mayo Clinic Cancer Center, Florida, reviews clinical trials that are investigating the optimal adjuvant treatment for patients with breast cancer.

Dr. Erba on Azacitidine and Gemtuzumab Ozogamicin

January 23rd 2013

Harry Erba, MD, PhD, discusses the results of a phase II study analyzing azacitidine and gemtuzumab ozogamicin as induction and post-remission therapy in patients of age 60 and older with previously untreated non-M3 AML.

Dr. Jagannath on Life Expectancy in Myeloma

January 22nd 2013

Sundar Jagannath, MD, Director, Multiple Myeloma Program, The Tisch Cancer Institute at The Mount Sinai Medical Center, details the advances in life expectancy for patients with multiple myeloma.

Dr. Ramalingam Explores Cytotoxics in Lung Cancer

January 22nd 2013

Suresh S. Ramalingam, MD, from Emory University's Winship Cancer Institute, explains that a number of new cytotoxic drugs are being developed in combination with targeted therapies, such as EGFR inhibitors.

Dr. DeRosa Discusses Nab-Paclitacel in Lung Cancer

January 21st 2013

William T. DeRosa, DO, from Carol G. Simon Cancer Center at Morristown Memorial Hospital, discusses subset analyses from the phase III CA031 trial that examined nab-paclitaxel in non-small cell lung cancer.

Dr. Zaks on the JAK2 Inhibitor SAR302503 in Myelofibrosis

January 21st 2013

Tal Zaks, MD, PhD, Sanofi Oncology, details a phase II randomized study of the JAK2 inhibitor SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera MF, or post-essential thrombocythemia MF.

Dr. Furman on Trials Examining Ibrutinib's Safety in CLL

January 18th 2013

Richard R. Furman, MD, from the Weill Cornell Medical Center, discusses the safety profile of the oral BTK inhibitor ibrutinib in both relapsed/refractory and treatment naive patients with chronic lymphocytic leukemia.

Dr. McCarthy on Eligibility Criteria for Allogeneic BMT

January 18th 2013

Philip L. McCarthy, MD, Director, Blood & Marrow Transplant Program, Department of Medicine, Roswell Park Cancer Institute, explains the factors that determine patient tolerability to allogeneic bone marrow transplant.

Dr. Li Reviews Afatinib Data From the LUX-Lung 3 Trial

January 17th 2013

Tianhong (Tina) Li, MD, PhD, from the UC Davis Comprehensive Cancer Center, discusses results from the LUX-Lung 3 trial that examined afatinib as a first-line treatment for patients with EGFR-positive advanced lung adenocarcinoma.

Dr. Gradishar Reviews Findings From the LEA Trial

January 17th 2013

William J. Gradishar, MD, from the Northwestern University Feinberg School of Medicine, reviews results from the phase III LEA trial that investigated add-on bevacizumab in breast cancer.

Dr. Smita Bhatia on Anthracycline-Related CHF

January 17th 2013

Smita Bhatia, MD, MPH, Population Sciences, City of Hope, Duarte, California, explains a clinical trial analyzing genetic susceptibility to anthracycline-related congestive heart failure in survivors of hematopoietic cell transplantation.

Dr. Fanale on Frontline Brentuximab in Lymphoma

January 16th 2013

Michelle A. Fanale, MD, from the MD Anderson Cancer Center, discusses a phase I trial that examined the frontline administration of brentuximab vedotin for patients with subtypes of lymphoma.

Dr. Sara Tolaney on Cabozantinib in Breast Cancer

January 16th 2013

Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute and Brigham and Women's Hospital, discusses trials investigating cabozantinib in breast cancer.